NCT05324319

Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients

Single Blinded Randomized Controlled Trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or ChAdOx1-S (Viral Vector) for Third Vaccination in Kidney Transplant Recipients Without SARS-CoV-2 Spike Protein Antibodies Following Full Vaccination

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized-controlled trial comparing homologous (mRNA vaccine) vs. heterologous (vector vaccine) for third SARS-CoV-2 vaccine dose in kidney transplant recipients not responding to initial prime-boost vaccination with an mRNA vaccine.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Ad26COVS1	Heterologous vaccination
DRUG	ChAdOx1 SARS2 Vaccine	Heterologous vaccination
DRUG	BNT162B2	Homologous vaccination
DRUG	mRNA-1273	Homologous vaccination

Timeline

• Start date: 2021-06-15
• Primary completion: 2022-07-31
• Completion: 2022-12-31
• First posted: 2022-04-12
• Last updated: 2022-04-20

Locations

1 site across 1 country: Austria